Pembrolizumab with local limb chemotherapy for sarcoma in arms or legs
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving pembrolizumab along with chemotherapy delivered directly into an arm or leg (isolated limb infusion) can shrink sarcoma tumors. It is for people with advanced or metastatic sarcoma in an arm or leg who can safely have this local treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 12 years old and be willing/able to sign consent (or assent with a parent/guardian).
- Have sarcoma that is confirmed by biopsy, and it must be advanced and/or metastatic.
- Be able to receive pembrolizumab as the standard treatment option (your team will confirm).
- Have tumors in the arm or leg that your doctor determines are eligible for isolated limb infusion.
- Have measurable tumor(s) on scan or by exam you can measure.
- Have had at least one prior treatment for sarcoma (or declined the standard treatment option).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether pembrolizumab, an immunotherapy that helps your immune system attack cancer cells, can shrink or slow growth in several ultra-rare sarcoma types that have come back or spread. It may be an option if your previous treatments have stopped working.
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
This Phase 2 trial studies whether combining pembrolizumab and cabozantinib can control advanced sarcoma that can’t be removed by surgery and has grown or returned after standard treatment. It may help shrink tumors and improve outcomes in adults who have limited treatment options left.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.